The DOI matches its Crossref record; 40 of the 40 references it cites were found in a registry or an index.
When good drugs go bad
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Incidence of Adverse Drug Reactions in Hospitalized Patients: A Meta-analysis of Prospective Studies
Lazarou, J., Pomeranz, B. H., & Corey, P. N. (1998) · JAMA · doi:10.1001/jama.279.15.1200 · Cited by 4,807
Effect of Rosiglitazone on the Risk of Myocardial Infarction and Death from Cardiovascular Causes
Nissen, S. E., & Wolski, K. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa072761 · Cited by 4,675
Adverse drug reactions: definitions, diagnosis, and management
Edwards, I. R., & Aronson, J. K. (2000) · The Lancet · doi:10.1016/s0140-6736(00)02799-9 · Cited by 2,979
Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy
Kahn, S. E., Haffner, S. M., Heise, M. A., Herman, W. H., Holman, R. R., Jones, N. P., Kravitz, B. G., Lachin, J. M., O'Neill, M. C., Zinman, B., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa066224 · Cited by 2,962
Drug-induced prolongation of the QT interval
Roden, D. M. (2004) · New England Journal of Medicine · doi:10.1056/nejmra032426 · Cited by 1,965
Self-citationUnder-Reporting of Adverse Drug Reactions: A Systematic Review
Hazell, L., & Shakir, S. A. W. (2006) · Drug Safety · doi:10.2165/00002018-200629050-00003 · Cited by 1,931
Valvular Heart Disease and the Use of Dopamine Agonists for Parkinson's Disease
Zanettini, R., Antonini, A., Gatto, G., Gentile, R., Tesei, S., & Pezzoli, G. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa054830 · Cited by 884
Rosiglitazone Evaluated for Cardiovascular Outcomes — An Interim Analysis
Home, P. D., Pocock, S. J., Beck-Nielsen, H., Gomis, R., Hanefeld, M., Jones, N. P., Komajda, M., & McMurray, J. J. V. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa073394 · Cited by 761
Pharmacogenomics and Individualized Drug Therapy
Eichelbaum, M., Ingelman-Sundberg, M., & Evans, W. E. (2006) · Annual Review of Medicine · doi:10.1146/annurev.med.56.082103.104724 · Cited by 720
Self-citationDopamine Agonists and the Risk of Cardiac-Valve Regurgitation
Schade, R., Andersohn, F., Suissa, S., Haverkamp, W., & Garbe, E. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa062222 · Cited by 718
Thiazolidinedione Use and Bone Loss in Older Diabetic Adults
Schwartz, A. V., Sellmeyer, D. E., Vittinghoff, E., Palermo, L., Lecka-Czernik, B., Feingold, K. R., Strotmeyer, E. S., Resnick, H. E., Carbone, L., Beamer, B. A., et al. (2006) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2005-2226 · Cited by 500
Drugs and Valvular Heart Disease
Roth, B. L. (2007) · New England Journal of Medicine · doi:10.1056/nejmp068265 · Cited by 479
Postmarketing Surveillance and Adverse Drug Reactions: Current Perspectives and Future Needs
Brewer, T., & Colditz, G. A. (1999) · JAMA · doi:10.1001/jama.281.9.824 · Cited by 327
Treatment of Parkinson's disease with pergolide and relation to restrictive valvular heart disease
Van Camp, G., Flamez, A., Cosyns, B., Weytjens, C., Muyldermans, L., Van Zandijcke, M., De Sutter, J., Santens, P., Decoodt, P., Moerman, C., et al. (2004) · The Lancet · doi:10.1016/s0140-6736(04)15945-x · Cited by 321
Uncertain Effects of Rosiglitazone on the Risk for Myocardial Infarction and Cardiovascular Death
Diamond, G. A., Bax, L., & Kaul, S. (2007) · Annals of Internal Medicine · doi:10.7326/0003-4819-147-8-200710160-00182 · Cited by 288
Pharmacogenomics: Challenges and Opportunities
Roden, D. M., Altman, R. B., Benowitz, N. L., Flockhart, D. A., Giacomini, K. M., Johnson, J. A., Krauss, R. M., McLeod, H. L., Ratain, M. J., Relling, M. V., et al. (2006) · Annals of Internal Medicine · doi:10.7326/0003-4819-145-10-200611210-00007 · Cited by 282
Self-citationDrug-induced liver injury: Summary of a single topic clinical research conference
Watkins, P. B., & Seeff, L. B. (2006) · Hepatology · doi:10.1002/hep.21095 · Cited by 279
Severe multivalvular heart disease: A new complication of the ergot derivative dopamine agonists
Horvath, J., Fross, R. D., Kleiner‐Fisman, G., Lerch, R., Stalder, H., Liaudat, S., Raskoff, W. J., Flachsbart, K. D., Rakowski, H., Pache, J., et al. (2004) · Movement Disorders · doi:10.1002/mds.20201 · Cited by 243
Valvular Heart Disease in Patients Taking Pergolide
Pritchett, A. M., Morrison, J. F., Edwards, W. D., Schaff, H. V., Connolly, H. M., & Espinosa, R. E. (2002) · Mayo Clinic Proceedings · doi:10.4065/77.12.1280 · Cited by 222
Postmarketing Surveillance—Lack of Vigilance, Lack of Trust
Fontanarosa, P. B. (2004) · JAMA · doi:10.1001/jama.292.21.2647 · Cited by 221
The Rosiglitazone Story — Lessons from an FDA Advisory Committee Meeting
Rosen, C. J. (2007) · New England Journal of Medicine · doi:10.1056/nejmp078167 · Cited by 207
Adverse Drug Reaction-Related Hospitalisations: A Nationwide Study in The Netherlands
van der Hooft, C. S., Sturkenboom, M. C. J. M., van Grootheest, K., Kingma, H. J., & H.Ch. Stricker, B. (2006) · Drug Safety · doi:10.2165/00002018-200629020-00006 · Cited by 186
The Ketolides: A Critical Review
Zhanel, G. G., Walters, M., Noreddin, A., Vercaigne, L. M., Wierzbowski, A., Embil, J. M., Gin, A. S., Douthwaite, S., & Hoban, D. J. (2002) · Drugs · doi:10.2165/00003495-200262120-00006 · Cited by 183
Clay, K. D., Hanson, J. S., Pope, S. D., Rissmiller, R. W., Purdum, P. P., & Banks, P. M. (2006) · Annals of Internal Medicine · doi:10.7326/0003-4819-144-6-200503210-00121 · Cited by 160
Thiazolidinedione Treatment Decreases Bone Mineral Density in Type 2 Diabetic Men
Yaturu, S., Bryant, B., & Jain, S. K. (2007) · Diabetes Care · doi:10.2337/dc06-2606 · Cited by 155
Johnson, T. N. (2003) · Toxicology · doi:10.1016/s0300-483x(03)00249-x · Cited by 124
The Record on Rosiglitazone and the Risk of Myocardial Infarction
Psaty, B. M., & Furberg, C. D. (2007) · New England Journal of Medicine · doi:10.1056/nejme078116 · Cited by 120
Pergolide use in Parkinson disease is associated with cardiac valve regurgitation
Baseman, D., O’Suilleabhain, P. E., Reimold, S. C., Laskar, S. R., Baseman, J. G., & Dewey, R. B. (2004) · Neurology · doi:10.1212/01.wnl.0000129842.49926.07 · Cited by 119
Ross, D. B. (2007) · New England Journal of Medicine · doi:10.1056/nejmp078032 · Cited by 115
Heart valvular disease in patients with Parkinson’s disease treated with high-dose pergolide
Camp, G. V., Flamez, A., Cosyns, B., Goldstein, J. W., Perdaens, C., & Schoors, D. (2003) · Neurology · doi:10.1212/01.wnl.0000083985.00343.f2 · Cited by 115
Expecting the Unexpected — Drug Safety, Pharmacovigilance, and the Prepared Mind
Trontell, A. E. (2004) · New England Journal of Medicine · doi:10.1056/nejmp048187 · Cited by 86
Effects of Thiazolidinediones on Bone Loss and Fracture
Murphy, C. E., & Rodgers, P. T. (2007) · Annals of Pharmacotherapy · doi:10.1345/aph.1k286 · Cited by 64
Is there still a role for spontaneous reporting of adverse drug reactions?
Lexchin, J. (2006) · Canadian Medical Association Journal · doi:10.1503/cmaj.050971 · Cited by 60
Diabetes drug pioglitazone (Actos): risk of fracture
Meymeh, R. H., & Wooltorton, E. (2007) · Canadian Medical Association Journal · doi:10.1503/cmaj.071177 · Cited by 52
Molokhia, M., & McKeigue, P. (2006) · Pharmacogenomics · doi:10.2217/14622416.7.4.633 · Cited by 47
Valvular Heart Disease in Patients Taking Pergolide
Waller, E. A., Kaplan, J., & Heckman, M. G. (2005) · Mayo Clinic Proceedings · doi:10.4065/80.8.1016 · Cited by 45
Rascol, O., Pathak, A., Bagheri, H., & Montastruc, J. (2004) · Movement Disorders · doi:10.1002/mds.20202 · Cited by 42
Canadian and US Drug Approval Times and Safety Considerations
Rawson, N. S. B., & Kaitin, K. I. (2003) · Annals of Pharmacotherapy · doi:10.1345/aph.1d110 · Cited by 37
Telithromycin and Acute Liver Failure
Graham, D. J. (2006) · New England Journal of Medicine · doi:10.1056/nejmc066372 · Cited by 30
Re-examining our approach to the approval and use of new drugs
Lee, S. K. (2006) · Canadian Medical Association Journal · doi:10.1503/cmaj.060581 · Cited by 1
Cited by
Polypharmacology: Challenges and Opportunities in Drug Discovery: Miniperspective
Anighoro, A., Bajorath, J., & Rastelli, G. (2014) · Journal of Medicinal Chemistry · doi:10.1021/jm5006463 · Cited by 1,131
Development of a Large-Scale De-Identified DNA Biobank to Enable Personalized Medicine
Roden, D., Pulley, J., Basford, M., Bernard, G., Clayton, E., Balser, Jr., & Masys, D. (2008) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2008.89 · Cited by 983
Self-citationPharmacogenomics of GPCR Drug Targets
Hauser, A. S., Chavali, S., Masuho, I., Jahn, L. J., Martemyanov, K. A., Gloriam, D. E., & Babu, M. M. (2018) · Cell · doi:10.1016/j.cell.2017.11.033 · Cited by 616
Identifying genetic risk factors for serious adverse drug reactions: current progress and challenges
Wilke, R. A., Lin, D. W., Roden, D. M., Watkins, P. B., Flockhart, D., Zineh, I., Giacomini, K. M., & Krauss, R. M. (2007) · Nature Reviews Drug Discovery · doi:10.1038/nrd2423 · Cited by 391
Self-citationWITHDRAWN—a resource for withdrawn and discontinued drugs
Siramshetty, V. B., Nickel, J., Omieczynski, C., Gohlke, B.-O., Drwal, M. N., & Preissner, R. (2016) · Nucleic Acids Research · doi:10.1093/nar/gkv1192 · Cited by 286
Retracted
Metadata
- Authors
- Giacomini, K. M., Krauss, R. M., Roden, D. M., Eichelbaum, M., Hayden, M. R., & Nakamura, Y.
- Venue
- Nature
- Published
- 2007-04
- Volume
- 446
- Issue
- 7139
- Pages
- 975-977
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- OpenAlex
- W1979845492
- Cited by
- 276
- References
- 40
- FWCI
- 13.92
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.